Cargando…
Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis
BACKGROUND AND OBJECTIVES: To simulate the cost-effectiveness of Mesenchymal Stromal Cell (MSC) therapy compared to sodium/glucose co-transporter 2 inhibitors (SGLT2i) or usual care (UC) in treating patients with Diabetic Kidney Disease (DKD). DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This Ma...
Autores principales: | Barry, Luke E., Crealey, Grainne E., Cockwell, Paul, Elliman, Stephen J., Griffin, Matthew D., Maxwell, Alexander P., O’Brien, Timothy, Perico, Norberto, O’Neill, Ciaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635741/ https://www.ncbi.nlm.nih.gov/pubmed/36331936 http://dx.doi.org/10.1371/journal.pone.0274136 |
Ejemplares similares
-
The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review
por: Elshahat, Sarah, et al.
Publicado: (2020) -
Hospital Costs and Fatality Rates of Traumatic Assaults by Mechanism in the US, 2016-2018
por: Barry, Luke E., et al.
Publicado: (2022) -
Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England
por: Nguyen, Nga T. Q., et al.
Publicado: (2018) -
An umbrella review of the acceptability of fiscal and pricing policies to reduce diet-related noncommunicable disease
por: Barry, Luke E, et al.
Publicado: (2023) -
Does the use of patient decision aids lead to cost savings? a systematic review
por: Scalia, Peter, et al.
Publicado: (2020)